Climb Bio, Inc. CLYM
11.66
(0.23)
(1.93%)
as of 25 Sep
- Market cap
- $682.9M
- P/E
- 0.0×
Follow CLYM
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (27.10%) | (30.92%) | (32.15%) | (25.65%) |
+8 more TTM periods Free account |
|
| (26.27%) | (29.90%) | (31.10%) | (25.09%) | ||
ROIC |
(71.73%) | (97.47%) | (71.43%) | (41.27%) | |
Return on Tangible Assets |
(31.77%) | (48.18%) | (60.36%) | (58.79%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.70) | (0.78) | (0.80) | (0.65) | |
Free Cash Flow |
(53.14) | (53.30) | (54.54) | (44.24) | |
Capital Expenditures |
(0.45) | — | (0.19) | — | |
Piotroski F-Score |
2.00 | 2.00 | 2.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(12.47%) | (20.69%) | (20.78%) | (16.76%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.91 | 1.01 | 0.91 | 0.87 | |
Depreciation/Fixed assets |
(2.29) | (7.10) | (7.56) | (6.98) | |
Capex/Depreciation |
0.28 | 0.00 | 0.09 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.69) | (0.78) | (0.80) | (0.65) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | 0.00 | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates